Citations

Institution: Mayo Clinic Clear

Showing 10 of 108162 citations.

Unique plasma metabolomic signatures of individuals with inherited disorders of long‐chain fatty acid oxidation
McCoin, Colin S. , Piccolo, Brian D. , Knotts, Trina A. , Matern, Dietrich , Gillingham, Melanie B. , Adams, Sean H. , Vockley, Jerry , Gillingham, Melanie B

Journal of Inherited Metabolic Disease | February 23, 2016 | Volume: 39 | Issue: 3 | Pages: 399-408

10.1007/s10545-016-9915-3 | PMID 26907176 Get It

AbstractBlood and urine acylcarnitine profiles are commonly used to diagnose long‐chain fatty acid oxidation disorders (FAOD: i.e., long‐chain hydroxy‐acyl‐CoA dehydrogenase [LCHAD] and carnitine palmitoyltransferase 2 [CPT2] deficiency), but the global metabolic impact of long‐chain FAOD has not been reported. We utilized untargeted metabolomics to characterize plasma metabolites in 12 overnight‐fasted individuals with FAOD (10 LCHAD, two CPT2) and 11 healthy age‐, sex‐, and body mass index (BMI)‐matched controls, with the caveat that individuals with FAOD consume a low‐fat diet supplemented with medium‐chain triglycerides (MCT) while matched controls consume a typical American diet. In plasma 832 metabolites were identified, and partial least squared‐discriminant analysis (PLS‐DA) identified 114 non‐acylcarnitine variables that discriminated FAOD subjects and controls. FAOD individuals had significantly higher triglycerides and lower specific phosphatidylethanolamines, ceramides, and sphingomyelins. Differences in phosphatidylcholines were also found but the directionality differed by metabolite species. Further, there were few differences in non‐lipid metabolites, indicating the metabolic impact of FAOD specifically on lipid pathways. This analysis provides evidence that LCHAD/CPT2 deficiency significantly alters complex lipid pathway flux. This metabolic signature may provide new clinical tools capable of confirming or diagnosing FAOD, even in subjects with a mild phenotype, and may provide clues regarding the biochemical and metabolic impact of FAOD that is relevant to the etiology of FAOD symptoms.
Longitudinal decline in mild‐to‐moderate Alzheimer's disease: Analyses of placebo data from clinical trials
Thomas, Ronald G. , Albert, Marilyn, Petersen, Ronald C. , Aisen, Paul

Alzheimer's & Dementia | February 23, 2016 | Volume: 12 | Issue: 5 | Pages: 598-603

10.1016/j.jalz.2016.01.002 | PMID 26917500 Get It

AbstractIntroductionAccurate estimates of cognitive and clinical decline rates are essential to the design of clinical trials in Alzheimer's disease (AD) dementia.MethodsTo investigate the trajectories of individuals enrolled in therapeutic trials in mild‐to‐moderate AD, we analyzed the placebo arm data from 20 clinical trials including over 4500 subjects. We analyzed decline as measured by two cognitive instruments, the cognitive subscale of the Alzheimer's Disease Assessment Scale (ADAScog) and the Mini‐Mental State Examination, and one clinical rating scale, the Clinical Dementia Rating Sum of Boxes.ResultsTrajectories were generally similar across trials and nearly linear. Greater cognitive impairment at baseline, younger age, and greater education were associated with increased rate of cognitive decline. Effect sizes for the ADAScog were generated as a function of population characteristics.DiscussionThese data will inform the design of future studies of potential disease‐modifying therapies for mild‐to‐moderate AD dementia.
Inappropriately Appropriate
Asirvatham, Samuel J. , Stevenson, William G. , Asirvatham, Samuel J

Circulation: Arrhythmia and Electrophysiology | February 23, 2016 | Volume: 9 | Issue: 3 | Pages: No page available

10.1161/circep.116.003608 | PMID 26902147 Get It

New and emerging therapies for the treatment of irritable bowel syndrome: an update for gastroenterologists
Foxx–Orenstein, Amy E.

Therapeutic Advances in Gastroenterology | February 23, 2016 | Volume: 9 | Issue: 3 | Pages: 354-375

10.1177/1756283x16633050 | PMID 27134665 Get It

Irritable bowel syndrome is a functional bowel disorder with gastrointestinal symptoms (e.g. abdominal pain, straining, urgency, incomplete evacuation, nausea, and bloating) that occur alongside bowel function alterations (i.e. constipation, diarrhea, or both). Patients with irritable bowel syndrome may also experience comorbid anxiety and depression. Irritable bowel syndrome is common, with a prevalence estimated between 3% and 28%, affecting patient health and quality of life. Patients with moderate or severe irritable bowel syndrome generally seek medical care, whereas those with milder symptoms may choose self-management. Most patients with irritable bowel syndrome receive outpatient care, but irritable bowel syndrome-related hospitalizations do occur. The pathophysiology of irritable bowel syndrome is multifactorial (i.e. genetics, immune components, changes in the gut microbiota, disturbances in physiologic stress response systems, and psychosocial factors). Management of irritable bowel syndrome can include lifestyle changes, dietary interventions, counseling, psychologic medication, and agents that affect gastrointestinal motility. A number of therapies have emerged in recent years with clinical trial data demonstrating efficacy and safety for patients with irritable bowel syndrome, including agents that target gastrointestinal motility (i.e. linaclotide), gastrointestinal opioid receptors (i.e. asimadoline, eluxadoline), and gut microbiota (i.e. rifaximin). Linaclotide has been shown to significantly improve stool frequency and abdominal pain compared with placebo in constipation-predominant irritable bowel syndrome (number needed to treat, 5.1). Asimadoline shows efficacy in patients with moderate-to-severe irritable bowel syndrome-related pain. Rifaximin provided adequate relief of global irritable bowel syndrome symptoms versus placebo for a significantly greater percentage of patients with diarrhea-predominant irritable bowel syndrome ( p < 0.001). Management that encompasses all aspects of irritable bowel syndrome (gastrointestinal symptoms) and comorbid psychologic symptoms (e.g. anxiety or depression) is important for improving overall patient health and well-being.
Sex-Specific Differences at Presentation and Outcomes Among Patients Undergoing Transcatheter Aortic Valve Replacement
Kodali, Susheel , Williams, Mathew , Doshi, Darshan , Hahn, Rebecca T. , Humphries, Karin H. , Douglas, Pamela S. , Mack, Michael J. , Xu, Ke , Svensson, Lars G. , Thourani, Vinod H. , Tuzcu, E. Murat , Weissman, Neil J., Leon, Martin B. , Kirtane, Ajay J. , Hahn, Rebecca T , Nkomo, Vuyisile T. , Cohen, David Jonathan , Douglas, Pamela S , Williams, Mathew

Annals of Internal Medicine | February 22, 2016 | Volume: 164 | Issue: 6 | Pages: 377

10.7326/m15-0121 | PMID 26903039 Get It

Surgically Constructed Double-Outlet Right Ventricle
Egbe, A, Connolly, Heidi M. , Qureshi, M. Yasir , Qureshi, Muhammad Y, Egbe, Alexander C. , Schaff, Hartzell V. , Qureshi, Muhammad Y

Circulation | February 22, 2016 | Volume: 133 | Issue: 8 | Pages: 765-767

10.1161/circulationaha.115.019312 | PMID 26903020 Get It

False Negative Cell-Free DNA Screening Result in a Newborn with Trisomy 13
Cao, Yang , Hoppman, Nicole L., Kerr, Sarah E. , Sattler, Christopher A., Borowski, Kristi, Wick, Myra , Highsmith, W. Edward, Borowski, Kristi S, Wick, Myra J, Aypar, Umut

Case Reports in Genetics | February 22, 2016 | Volume: 2016 | Issue: No issue available | Pages: 1-5

10.1155/2016/7397405 | PMID 26998368 Get It

Background.Noninvasive prenatal screening (NIPS) is revolutionizing prenatal screening as a result of its increased sensitivity, specificity. NIPS analyzes cell-free fetal DNA (cffDNA) circulating in maternal plasma to detect fetal chromosome abnormalities. However, cffDNA originates from apoptotic placental trophoblast; therefore cffDNA is not always representative of the fetus. Although the published data for NIPS testing states that the current technique ensures high sensitivity and specificity for aneuploidy detection, false positives are possible due to isolated placental mosaicism, vanishing twin or cotwin demise, and maternal chromosome abnormalities or malignancy.Results.We report a case of false negative cell-free DNA (cfDNA) screening due to fetoplacental mosaicism. An infant male with negative cfDNA screening result was born with multiple congenital abnormalities. Postnatal chromosome and FISH studies on a blood specimen revealed trisomy 13 in 20/20 metaphases and 100% interphase nuclei, respectively. FISH analysis on tissues collected after delivery revealed extraembryonic mosaicism.Conclusions.Extraembryonic tissue mosaicism is likely responsible for the false negative cfDNA screening result. This case illustrates that a negative result does not rule out the possibility of a fetus affected with a trisomy, as cffDNA is derived from the placenta and therefore may not accurately represent the fetal genetic information.
Safety and Accuracy of Percutaneous Image-Guided Core Biopsy of the Spleen
Olson, Michael C. , Atwell, Thomas D. , Harmsen, William S. , Konrad, Aaron, King, Rebecca L. , Lin, Yi , Wall, Darci J., Harmsen, William Scott, Lin, Yi

American Journal of Roentgenology | February 22, 2016 | Volume: 206 | Issue: 3 | Pages: 655-659

10.2214/ajr.15.15125 | PMID 26901024 Get It

Anaesthesia for hip fracture surgery in adults
Guay, Joanne, Parker, Martyn J. , Gajendragadkar, Pushpaj R., Kopp, Sandra L. , Kopp, Sandra

Cochrane Database of Systematic Reviews | February 22, 2016 | Volume: 2017 | Issue: 3 | Pages: No page available

10.1002/14651858.cd000521.pub3 | PMID 26899415 Get It

Cardiovascular manifestations of renovascular hypertension in diabetic mice
Kashyap, Sonu , Engel, Sean, Osman, Mazen, Al-Saiegh, Yousif , Wongjarupong, Asarn, Grande, Joseph P.

PeerJ | February 22, 2016 | Volume: 4 | Issue: No issue available | Pages: e1736

10.7717/peerj.1736 | PMID 26925344 Get It

Purpose. Type 2 diabetes is the leading cause of end stage renal disease in the United States. Atherosclerotic renal artery stenosis is commonly observed in diabetic patients and impacts the rate of renal and cardiovascular disease progression. We sought to test the hypothesis that renovascular hypertension, induced by unilateral renal artery stenosis, exacerbates cardiac remodeling in leptin-deficient (db/db) mice, which serves as a model of human type II diabetes. Methods. We employed a murine model of renovascular hypertension through placement of a polytetrafluoroethylene cuff on the right renal artery in db/db mice. We studied 109 wild-type (non-diabetic, WT) and 95 db/db mice subjected to renal artery stenosis (RAS) or sham surgery studied at 1, 2, 4, and 6+ weeks following surgery. Cardiac remodeling was assessed by quantitative analysis of the percent of myocardial surface area occupied by interstitial fibrosis tissue, as delineated by trichrome stained slides. Aortic pathology was assessed by histologic sampling of grossly apparent structural abnormalities or by section of ascending aorta of vessels without apparent abnormalities. Results. We noted an increased mortality in db/db mice subjected to RAS. The mortality rate of db/db RAS mice was about 23.5%, whereas the mortality rate of WT RAS mice was only 1.5%. Over 60% of mortality in the db/db mice occurred in the first two weeks following RAS surgery. Necropsy showed massive intrathoracic hemorrhage associated with aortic dissection, predominantly in the ascending aorta and proximal descending aorta. Aortas from db/db RAS mice showed more smooth muscle dropout, loss of alpha smooth muscle actin expression, medial disruption, and hemorrhage than aortas from WT mice with RAS. Cardiac tissue from db/db RAS mice had more fibrosis than did cardiac tissue from WT RAS mice. Conclusions. db/db mice subjected to RAS are prone to develop fatal aortic dissection, which is not observed in WT mice with RAS. The db/db RAS model provides the basis for future studies directed towards defining basic mechanisms underlying the interaction of hypertension and diabetes on the development of aortic lesions.